Previous close | 47.30 |
Open | 47.30 |
Bid | 45.60 |
Ask | 49.60 |
Strike | 145.00 |
Expiry date | 2024-07-19 |
Day's range | 47.30 - 47.30 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the initial acceptance period is expected to occur on 23 May 2024Additional statutory acceptance period is expected to end on 30 May 2024 at 24:00 hours CESTTransaction strengthens the Novartis pipeline in oncology, adding pelabresib, a late-stage BET inhibitor for myelofibrosis and tulmimetostat, an early-s